Agrylin 0,5 mg Capsule
PDF Leaflet Revision Date: 31 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce platelet count in essential thrombocythemia and other myeloproliferative disorders.
Dosage (summary)
0.5 mg four times daily or 1 mg twice daily for adults.
Onset of Action / Duration
Onset: 7-14 days, Duration: 4-12 weeks
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; potential fetal harm. Discontinue breastfeeding during treatment.
Key Drug Interactions
- Aspirin
- CYP1A2 inhibitors
- Digoxin
- Warfarin
Contraindications
- Severe hepatic impairment
- Hypersensitivity
Common side effects
- Headache
- Palpitations
- Nausea
- Oedema
- Diarrhoea
Counselling Points
- Monitor platelet counts regularly
- Avoid abrupt discontinuation
- Report signs of thrombotic complications
Serious warnings
- Cardiovascular risks
- Thrombotic risk
- QT interval prolongation
Important Disclaimer
The Agrylin 0,5 mg Capsule professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
